Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2976961 | 1.00 | NPC1 (0.50) | NPC1ACHELMNAEPHX2SMN1; SMN2 | |
| SCHEMBL11228022 | 1.00 | NPC1 (0.50) | NPC1ACHELMNAEPHX2SMN1; SMN2 | |
| SCHEMBL15362702 | 1.00 | NPC1 (0.50) | NPC1ACHELMNAEPHX2SMN1; SMN2 | |
| SCHEMBL14359727 | 0.97 | NPC1 (0.46) | NPC1ACHELMNAEPHX2SMN1; SMN2 | |
| SCHEMBL28236249 | 0.93 | NPC1 (0.45) | NPC1ACHELMNAEPHX2SMN1; SMN2 | |
| SCHEMBL22414144 | 0.93 | NPC1 (0.45) | NPC1ACHELMNAEPHX2SMN1; SMN2 | |
| SCHEMBL18330523 | 0.92 | — | — | |
| SCHEMBL9958288 | 0.91 | NPC1 (0.44) | NPC1ACHELMNAEPHX2SMN1; SMN2 | |
| SCHEMBL11350663 | 0.91 | NPC1 (0.42) | NPC1EPHX2CA2 | |
| SCHEMBL3152054 | 0.89 | NPC1 (0.42) | NPC1LMNAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111171272-A | Novel composite ion solvent-free waterborne polyurethane and preparation method thereof | 山东天庆科技发展有限公司 | 2020-05-19 | — | — | CN | claimed |
| CN-114395103-B | Aqueous polyurethane impregnating resin for microfiber synthetic leather and preparation method thereof | 明新梅诺卡(江苏)新材料有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230312605-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2023064366-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-8058565-B2 | Wiring board, semiconductor device, and method for manufacturing wiring board | NEC CORPORATION (JP) | 2011-11-15 | — | — | US | disclosed |
| US-20070274060-A1 | WIRING BOARD, SEMICONDUCTOR DEVICE, AND METHOD FOR MANUFACTURING WIRING BOARD | NEC CORPORATION (JP) | 2007-11-29 | — | — | US | disclosed |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1228070-B1 | HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | HOFFMANN LA ROCHE (CH) | 2007-02-07 | — | — | EP | disclosed |
| US-20050232915-A1 | Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer | NAKAJIMA MOTOWO | 2005-10-20 | — | — | US | disclosed |
| EP-0929517-B1 | HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2002-06-12 | — | — | EP | disclosed |
| US-20020038045-A1 | Hydroxamic acid derivatives | NOVARTIS AG (CH) | 2002-03-28 | — | — | US | disclosed |
| CN-1070524-C | Non-aqueous ink for ball-point pen | MITSUBISHI PENCIL CO (JP) | 2001-09-05 | — | — | CN | disclosed |
| WO-2001029042-A1 | HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
| EP-0929517-A1 | HYDROXAMIC ACID DERIVATIVES | Novartis AG (CH) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998014424-A1 | HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 1998-04-09 | — | — | WO | disclosed |
| US-5414144-A | Detergent, solvent, film-forming agent | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1995-05-09 | — | — | US | disclosed |
| US-4317942-A | Odoriferous 2-alkoxyethyl-cycloalkyl-ethers | CHEMISCHE WERKE HUELS, AKTIENGESELLSCHAFT (DE) | 1982-03-02 | — | — | US | disclosed |
| EP-0022462-B1 | 2-ALKOXYETHYL-CYCLOALKYL-ETHERS, COMPOSITIONS CONTAINING THESE, AND THEIR UTILIZATION FOR THE PREPARATION OF ODORANT COMPOSITIONS | CHEMISCHE WERKE HÜLS AG (DE) | 1981-11-25 | — | — | EP | disclosed |
| EP-0022462-A1 | 2-Alkoxyethyl-cycloalkyl-ethers, compositions containing these, and their utilization for the preparation of odorant compositions | CHEMISCHE WERKE HÜLS AG (DE) | 1981-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312605-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK2, DYRK1B | NPC1 4100/4885ACHE 3271/4885LMNA 3598/4885 |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | NFKBIA, IKBKG, NFKB2 | NPC1 4389/4885ACHE 3533/4885LMNA 4358/4885 |
| US-20050232915-A1 | Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer | MMP3, TIMP3, MMP25 | NPC1 3494/4885ACHE 2442/4885LMNA 1706/4885 |
| US-20020038045-A1 | Hydroxamic acid derivatives | TNF, HCAR2, HCAR1 | NPC1 4466/4885ACHE 2048/4885LMNA 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.